Ceretas (ASX: CTS) Debuts on ASX After Raising $8 Million IPO to Advance Alzheimer's Ultrasound Therapy Trials

Details of Ceretas' IPO and Market Entry

On 23 July 2026, Ceretas Limited successfully listed on the Australian Securities Exchange following an $8 million initial public offering priced at 25 cents per share. This listing established a market capitalisation of $17.8 million, providing the company with essential capital to progress its clinical development and expand preclinical research efforts. Entering the public market represents a significant advancement for Ceretas, enabling broader investor engagement in its innovative therapeutic platform.

The IPO pricing and market cap position Ceretas firmly within the early-stage biotech segment of the ASX, where companies typically raise funds to support clinical trials and regulatory approval pathways. The $8 million raised is earmarked specifically to advance the Phase 2 CERE-CALM trial targeting Alzheimer's patients and to support ongoing preclinical studies. This focused capital deployment underscores Ceretas' commitment to validating clinical efficacy while expanding its technology's therapeutic potential.

Innovative Therapeutic Ultrasound Platform with Dual Action

Ceretas has engineered a portable, non-invasive therapeutic ultrasound platform that delivers low-intensity focused ultrasound through the skull to target brain tissue. This technology operates via two distinct mechanisms: neuromodulation, which modulates neural circuits responsible for memory, cognition, and behavioural symptoms of dementia; and blood-brain barrier opening, which aims to facilitate clearance of pathological proteins and enhance delivery of therapeutic agents directly to brain tissue.

This dual-mechanism approach offers multiple therapeutic avenues for treating Alzheimer's and other neurodegenerative diseases. The ability to non-invasively deliver low-intensity ultrasound through the skull overcomes significant challenges posed by the blood-brain barrier in central nervous system treatments. The platform's portability suggests potential for both clinical and home-based applications, although commercial deployment strategies remain undisclosed. The technology's foundation in extensive academic research provides a robust scientific basis for ongoing development.

Technology Originating from University of Queensland's Queensland Brain Institute

The Ceretas platform is the culmination of more than a decade of research at The University of Queensland's Queensland Brain Institute, supported by approximately $20 million in research funding. This extensive development timeline reflects the rigorous preclinical and early clinical validation necessary for neurological innovations. The academic roots lend scientific credibility, with the technology having undergone peer-reviewed validation.

Founded by a team dedicated to translating Professor Jürgen Götz's pioneering research into clinical applications, Ceretas exemplifies successful academic-to-commercial transition. The company maintains ongoing collaborations with the Queensland Brain Institute, including independent Phase 2 trials such as the AGIFUS study funded by Queensland Health, which evaluates the technology for Alzheimer's-related agitation.

Phase 1 Clinical Trial Outcomes and Safety Profile

In 2024, a first-in-human Phase 1 trial conducted at the Queensland Brain Institute evaluated low-intensity focused ultrasound neuromodulation in 12 Alzheimer's patients. The study demonstrated that the treatment was rapid, safe, and well tolerated. Importantly, early indications of benefit for behavioural symptoms were observed, informing the design of the Phase 2 program. These findings were published in the peer-reviewed journal Brain Communications in December 2025, providing independent validation of safety and preliminary efficacy.

The Phase 1 results represent a key de-risking milestone, showing that ultrasound delivery can be safely administered without significant adverse effects. The observed behavioural symptom improvements focus the Phase 2 trial on behavioural and psychological symptoms of dementia (BPSD), a therapeutic area with limited effective treatments. Publication in a reputable journal enhances scientific credibility and supports regulatory progression.

Design and Scope of the Phase 2 CERE-CALM Trial

The Phase 2 CERE-CALM trial is a randomized, double-blind, sham-controlled study assessing low-intensity focused ultrasound neuromodulation for behavioural and psychological symptoms of dementia in Alzheimer's patients aged 50 and above. The trial plans to enroll 66 participants, randomized 2:1 to active treatment or sham control, with at least 60 completing the study. Treatment involves six sessions over 12 weeks: four weekly followed by two monthly sessions, enabling evaluation of both immediate and sustained effects.

The primary endpoint is the change in neuropsychiatric symptom burden measured by the Neuropsychiatric Inventory (NPI) total score at week 6 compared to baseline. Secondary endpoints include caregiver distress at weeks 6 and 12, durability of treatment effect at week 12, and overall safety and tolerability. The trial is registered under ACTRN12626000738325 on the Australian and New Zealand clinical trial registry, ensuring transparency.

Addressing Significant Unmet Needs in Dementia Care

Dementia affects an estimated 57 million people globally, according to the World Health Organization. Behavioural and psychological symptoms of dementia (BPSD) pose substantial clinical challenges, increasing caregiver burden and accelerating transitions to residential care. Existing treatments largely rely on antipsychotics, which have safety concerns and variable efficacy in elderly patients.

Ceretas’ focus on BPSD in its Phase 2 trial targets this critical unmet need within the Alzheimer's population. Symptoms such as agitation and aggression severely impact quality of life for patients and caregivers. Developing a non-pharmacological, non-invasive therapy could fill a vital clinical gap. CEO Dr Rachel de las Heras highlighted the absence of broadly available treatments for the 57 million people living with dementia worldwide, underscoring the company’s strategic positioning.

Experienced Leadership and Governance

Ceretas is guided by a seasoned management team with expertise in medical technology development and commercialization. CEO and Managing Director Dr Rachel de las Heras leads the company through its pivotal clinical development phase. Chairperson John Keep heads a board noted for experience and a track record of delivering shareholder value. The leadership team is tasked with navigating regulatory and clinical pathways to bring this novel neurological therapy to market. The ASX listing and governance structures reflect commitment to institutional investor standards.

The board and management’s experience serves as a risk mitigator for investors, enhancing the likelihood of successful clinical and regulatory milestones. While detailed biographies were not disclosed at listing, the team’s background in medical devices and shareholder value creation is emphasized, indicating strategic and investor relations strengths.

Advancing Blood-Brain Barrier Opening Research

Beyond neuromodulation, Ceretas is advancing preclinical research into blood-brain barrier opening, a second mechanism enabled by its ultrasound platform. The blood-brain barrier restricts delivery of many therapeutic agents to the brain. Temporarily opening this barrier with focused ultrasound could facilitate delivery of disease-modifying therapies currently limited by poor brain penetration.

IPO funds will support these preclinical studies, reflecting Ceretas’ commitment to developing this complementary therapeutic avenue. Success in this area could enable combination therapies with amyloid or tau-targeting drugs, expanding the platform’s clinical applications and long-term value potential.

Regulatory Strategy and Clinical Development Pathway

Ceretas is following established regulatory pathways for novel medical devices treating serious neurological conditions, progressing from Phase 1 to Phase 2 trials under oversight by the Therapeutic Goods Administration and equivalent bodies. The CERE-CALM Phase 2 trial is designed as a proof-of-concept study to generate efficacy and safety data in a larger cohort, informing future regulatory submissions and potential expanded access.

The company emphasizes transparency through clinical trial registration and peer-reviewed publications. Specific timelines for trial completion, regulatory filings, or commercialization remain undisclosed, reflecting typical clinical development uncertainties. Demonstrating safety and efficacy will be critical for regulatory approval and market entry.

Competitive Landscape and Differentiation

Ceretas’ portable, non-invasive ultrasound platform offers a unique approach in a competitive field including pharmaceuticals, other device therapies, and emerging technologies. Its non-invasive, dual-mechanism design provides advantages over surgical or invasive treatments. The technology’s academic foundation and Phase 1 safety data enhance its competitive position. However, detailed comparisons with other therapies have not been disclosed.

Targeting BPSD initially allows Ceretas to focus on an area with fewer competing therapies, potentially easing early clinical development challenges. The platform’s capacity to facilitate drug delivery via blood-brain barrier opening may create partnership opportunities and additional differentiation. As an Australian neurotechnology developer, Ceretas aligns with national innovation initiatives in medical technology.

Risks and Development Challenges

As with all clinical-stage medical device companies, Ceretas faces risks including the possibility that the Phase 2 CERE-CALM trial may not demonstrate statistically significant benefits over sham control. Neurological trials often encounter placebo effects, enrollment difficulties, safety concerns, or participant dropout, which could impact data quality. Regulatory approvals remain uncertain despite positive trial outcomes. The technology has yet to be tested in larger Phase 2 or Phase 3 trials, and early promising data may not predict broader success.

Additional risks include reliance on key personnel during the transition from academic research to commercialization, substantial capital needs for clinical and regulatory progression, and evolving reimbursement landscapes. Manufacturing and distribution capabilities for the ultrasound device at scale have not been proven, potentially affecting commercialization timelines. Investors should carefully consider these factors when evaluating Ceretas’ long-term prospects.